SCHEMBL2664655

SCHEMBL2664655

O=C(Nc1nnc(C(=O)O)s1)c1cc(OCc2ccccc2Cl)cc(OCc2ccccc2Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.52
NR4A2 P43354 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
CSNK2A2 P19784 1/20 0.49
CSNK2A1 P68400 1/20 0.49
RARA P10276 1/20 0.47
RARB P10826 1/20 0.47
RARG P13631 1/20 0.47
LMNA P02545 3/20 0.45
ALDH1A1 P00352 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
STAT3 P40763 1/20 0.44
BLM P54132 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664665 0.89 GCK (0.49) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664658 0.87 HTT (0.45) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664657 0.86 SMN1; SMN2 (0.54) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664649 0.84 POLQ (0.51) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664586 0.84 GCK (0.46) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL1796180 0.83 CSNK2A2 (0.55) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664648 0.82 SMN1; SMN2 (0.60) NPC1RAB9ALMNAALDH1A1RXFP1
SCHEMBL2664659 0.81 KDM4E (0.60) NPC1RAB9AALDH1A1MEN1MAPT
SCHEMBL2664647 0.81 GCK (0.49) GCKNR4A2NPC1RAB9ACSNK2A2
SCHEMBL2664591 0.80 RAB9A (0.55) GCKNR4A2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 GCK 2/4885NR4A2 2186/4885NPC1 1139/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 GCK 2/4885NR4A2 2186/4885NPC1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.